Subscribe
Funding & M&A
4 min read

Snout Raises $110M to Finance Vet Bills as Pet Care Costs Surge

Snout has raised $110 million, $10M in Series A funding and $100M in debt financing, to scale its no-interest, no-credit-check wellness plans for veterinary care. The raise signals investor confidence in pet fintech as vet costs surge and traditional financing options leave many pet owners behind.

Written by
The Underbite
Published on
February 9, 2026
Snout Raises $110M to Finance Vet Bills as Pet Care Costs Surge

Snout, a pet wellness financing platform, has raised $110 million in combined debt and equity to scale its no-interest, no-credit-check payment plans for veterinary care. For operators in pet services, the raise signals growing investor appetite for fintech solutions that sit between pet owners and rising vet bills — and a potential shakeup in how clinics get paid.

What Happened

Snout announced $10 million in Series A funding led by Footwork, alongside a $100 million debt facility from Clear Haven Capital Management. Other Series A participants include Bread and Butter Ventures, Pear, and Restive Ventures.

The company, founded in 2023 by Emily Dong, offers wellness plans that let pet owners pay for preventive vet care in monthly installments averaging $65. Unlike traditional financing options like CareCredit or Scratchpay, Snout requires no credit check and charges no interest. Clinics receive payment upfront; the debt facility funds the float.

Dong previously founded Pawprint, a pet records management platform acquired by Metamorphosis Partners in 2020. Her return to pet fintech with a capital-intensive model suggests she sees a structural gap in how veterinary care gets financed.

The announcement comes as vet costs have jumped roughly 40% in recent years, with veterinary services inflation running at 7.8% year-over-year. More than half of U.S. pet owners report skipping needed vet care due to cost, creating both a consumer pain point and a revenue problem for clinics.

Why It Matters

This raise positions Snout as a serious challenger in pet healthcare financing — a category that's been dominated by credit-based models with meaningful friction.

1. The debt facility is the real signal. The $100M from Clear Haven isn't venture capital optimism — it's underwriting confidence. Snout is betting that pet owners enrolled in wellness plans will reliably pay $65/month. If the loss rates are manageable, this model scales. If not, that debt facility becomes a problem.

2. No credit check changes the addressable market. CareCredit and Scratchpay serve pet owners who can pass credit checks. Snout's model reaches the segment that can't — or won't — apply for credit. In a market where cost is the primary barrier to vet care, removing the credit gate could meaningfully expand clinic revenue.

3. The wellness plan wrapper matters. Snout isn't marketing "financing" — it's marketing "wellness plans." That framing shifts the relationship from transactional (pay for this emergency) to ongoing (subscribe for preventive care). For clinics, that means more predictable revenue and potentially higher lifetime value per patient.

4. Competitive pressure on existing players. CareCredit (Synchrony) has dominated vet financing for years. Scratchpay, Cherry, and others have chipped away with BNPL models. Snout's approach — combining wellness plan packaging with debt-funded, zero-interest financing — represents a different competitive angle. Watch for CareCredit to respond with similar offerings.

For vet clinic operators evaluating financing partners, Snout adds another option. The question is whether "wellness plan" positioning actually changes pet owner behavior, or whether it's just repackaged financing with a friendlier name.

What to Watch

Clinic adoption velocity: Snout's model requires direct partnerships with vet practices. How quickly can they build distribution? The debt facility gives them capital to deploy; the constraint is clinic sales.

Loss rates and unit economics: The no-credit-check model is a bet on pet owner reliability. If defaults spike, the debt facility terms could tighten. Watch for any signals about repayment performance.

Response from incumbents: CareCredit has distribution advantages Snout can't match overnight. If wellness plan financing gains traction, expect Synchrony to launch competing products through its existing clinic network.

Pet insurance overlap: Snout's wellness plans cover preventive care — the same category most pet insurance excludes. That's complementary positioning today, but could create friction if insurers expand into wellness coverage.

Subscribe to newsletter

Join our newsletter to stay up to date on features and releases.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.

What's Happening

Other News

More stories shaping the pet industry this week. From funding rounds and product launches to regulatory shifts and retail strategy, stay ahead of what's driving the market.

Read article
Vetspire Splits From Thrive, Lands a Battery Ventures Backing
Funding & M&A
4 min read

Vetspire Splits From Thrive, Lands a Battery Ventures Backing

Vetspire has spun out of Thrive Pet Healthcare's orbit with a growth investment from Battery Ventures and a new CEO, Zachary Seely. The AI-powered practice management platform, used by more than 800 veterinary hospitals and clinics, will operate independently while Thrive remains a customer. The deal tests whether AI-native vet software can draw institutional capital without a strategic parent underwriting it.

Read article
Read article
PetMeds Revenue Falls 20% as Takeover Fight Drags On
Earnings
6 min read

PetMeds Revenue Falls 20% as Takeover Fight Drags On

PetMeds' first-quarter revenue fell 19.9% to $41.0 million and cash reserves dropped to $13.1 million, even as the company narrowed its net loss to $6.1 million from $34.2 million a year earlier. The results land as an unsolicited $3-a-share buyout offer from SilverCape Investments remains on the table and a $37 million sale-leaseback of its headquarters awaits closing.

Read article
Read article
FDA Clears Zoetis Drug for Screwworm as Outbreak Spreads North
Regulatory
4 min read

FDA Clears Zoetis Drug for Screwworm as Outbreak Spreads North

The FDA granted Zoetis an emergency use authorization for Simparica Trio to treat New World screwworm in dogs, the first product cleared specifically for the threat. Texas has already begun requiring treatment before dogs cross certain lines, putting boarding facilities, transporters, and border-state vet practices under a new compliance mandate.

Read article
View all articles